

Info Sheet for Technical description

No.0022

Organization

* Mandatoty fields

Name of Organization*	Human Life CORD Japan Inc.	
Address, City, States, Zip, Country*	1-9-10, Nihonbashi-horidomecho, Chuo-ku, Tokyo, 103-0012, Japan	
URL	https://humanlifecord.com/en/	
Brief Descriptions of Organization* (Approx. 100 words)	Human Life CORD Japan Inc. (HLC), founded in April 2017 and based in Tokyo, is a clinical-stage regenerative medicine startup specializing in developing and manufacturing human umbilical cord-derived mesenchymal stromal cells (UC-MSCs) to tackle with rare/intractable, age-related diseases, etc. Through patented technologies developed with the Institute of Medical Science, University of Tokyo (IMSUT), HLC is advancing clinical and preclinical research to develop pioneering cell therapies with UC-MSCs in NIPCs, sarcopenia and some autoimmune diseases. With strategic manufacturing collaboration with New York Blood Center Enterprises, HLC aims to establish a highly reproducible, scalable and sustainable platform, making advanced cell therapies more accessible worldwide.	
Contact address	Name*	Akihito Nakata, Ph.D.
	Department* / Position	Executive Officer, Chief Strategy Officer, Corporate Strategy & Business Development
	E-mail* / TEL	anakata20@humanlifecord.com

What kind of technology do you want to offer? *

- ☒ **A.** Clinical Development Pipelines → Please see **Sheet [A]**
- ☐ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- ☒ **C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet [C]**
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

☒ Yes

☐ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☐ Series A
- ☐ Series B
- ☒ Series C
- ☐ Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☒ Yes	Human Life CORD Japan Inc. is actively seeking for global partnering opportunities. We would be grateful if FIRM would support us in accelerating our partnering activities in a proactive manner. We can dispatch our presentation materials to FIRM.
☐ No	

Filled in by*

Date*

Akihito Nakata, Ph.D.

8-Aug-25

Sheet [C] Platform Technologies *that are not included in Group B***Info Sheet for Technical overview**

No. C-0022

* Mandatoty fields

Title***Globalizing a Japan-Origin UC-MSC Therapy Ecosystem Through Scalable, Cross-Border Collaboration****Description***

Human Life CORD Japan Inc. serves as a central hub for the development of a comprehensive, end-to-end supply chain for human umbilical cord-derived mesenchymal stromal cell (UC-MSC) products in Japan, in close collaboration with a network of trusted partners. In parallel, we are deepening strategic manufacturing alliances in the United States, most notably with New York Blood Center Enterprises. Leveraging our proprietary, Japan-origin cell therapy ecosystem, we are actively pursuing global expansion. At the core of this effort is a Japan-U.S. collaborative framework aimed at harmonizing quality standards, establishing a highly reproducible, scalable, and sustainable global manufacturing platform. Through partnerships with local stakeholders in key markets, we aim to co-develop regionally adapted business models that maximize access to advanced cell therapies where they are most needed.

Filled in by*

Akihito Nakata, Ph.D.

Date*

8-Aug-25